arrow
D

Daniel Rayson

Dalhousie University
H指数:38
被引数:5,158

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CCTG MA40: DOUBLE-BLIND PLACEBO CONTROLLED PHASE III TRIAL OF FULVESTRANT AND IPATASERTIB FOR ADVANCED HER-2 NEGATIVE AND ESTROGEN RECEPTOR POSITIVE (ER plus ) BREAST CANCER POST FIRST LINE CDK 4/6 AND AROMATASE INHIBITOR THERAPY (FINER)
2023-03-010
PRE
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

帕妥珠单抗联合曲妥珠单抗和紫杉烷一线治疗HER2-positive局部复发或转移性乳腺癌的初步安全性和有效性 (PERUSE)

2019-05-0189
OAAI
Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers
2019-02-1213
PREAI
Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy
2016-07-01191
OAAI
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer
2016-04-2646
PREAI
Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization

2013美国临床肿瘤学会/美国病理学家学院指南对浸润性乳腺癌人类表皮生长因子受体2 (HER2) 检测的影响: 通过荧光原位杂交评估HER2基因扩增为 “模棱两可” 的肿瘤

2015-06-0959
PREAI